OR WAIT null SECS
© 2023 MJH Life Sciences and Pharmaceutical Commerce. All rights reserved.
© 2023 MJH Life Sciences™ and Pharmaceutical Commerce. All rights reserved.
August 07, 2023
A dive into the issue of evidence gaps, plus the case for a chief access officer.
June 02, 2023
The latest on its implementation—and the implications for biopharma.
March 31, 2023
How various factors are affecting the amount of funds allocated to healthcare.
February 09, 2023
New Pharma Commerce column addresses the relevance of pricing.
December 08, 2022
Exploring the legislation's diverging requirements between regulatory agencies and global payers, and its impact on the commercial results of biopharma companies
February 25, 2010
Shared-risk or ‘pay for performance’ agreements between drugmakers and payers can represent uncertain rewards for both parties. Use strategic planning before entering into them